<DOC>
	<DOCNO>NCT02654470</DOCNO>
	<brief_summary>The WATCHMAN™ Left Atrial Appendage Closure ( LAAC ) Technology intend prevent thrombus embolization leave atrial appendage reduce risk life-threatening bleeding event patient non-valvular atrial fibrillation eligible anticoagulation therapy contraindication anticoagulation therapy .</brief_summary>
	<brief_title>Watchman FLX Left Atrial Appendage Closure Device Post Approval Study</brief_title>
	<detailed_description>The WATCHMAN™ Left Atrial Appendage Closure ( LAAC ) Technology intend prevent thrombus embolization leave atrial appendage reduce risk life-threatening bleeding event patient non-valvular atrial fibrillation eligible anticoagulation therapy contraindication anticoagulation therapy .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>1 . Subjects eligible WATCHMAN device accord current international local guideline currently approve indication per physician discretion ; 2 . Subject willing capable providing informed consent participate test associate clinical investigation approve clinical investigational center 3 . Subjects whose age 18 year , legal age give inform consent specific state national law . 1 . Subjects currently enrol another investigational study registry would directly interfere current study , except Subject participate mandatory governmental registry , purely observational registry associate treatment . Each instance bring attention sponsor determine eligibility 2 . The subject unable willing complete followup visit examination duration study 3 . Women childbearing potential , plan become , pregnant time study ( method assessment upon physician 's discretion ) ; 4 . Documented life expectancy le 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>